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Using Repeatable Battery for the Assessment of Neuropsychological Status (RBANS), previous study showed
significant gender differences for cognitive deficits in immediate and delayed memory in schizophrenia
patients. However, RBANS does not include reasoning and problem solving, and social cognition. These
cognitive functions can significantly affect the outcomes and daily life in patients. This study examined the
gender differences of cognition using the measurement and treatment research to improve cognition in
schizophrenia (MATRICS) consensus cognitive battery (MCCB), especially focusing on reasoning and
problem solving, and social cognition in schizophrenia patients. The results showed that healthy controls
exemplified better cognition than patients in both genders in all examined MCCB scores. Male healthy
controls had better reasoning and problem solving and working memory than females, but these gender
differences were not presented in schizophrenia patients. Also, male schizophrenia patients showed worse
cognition than females on social cognition, processing speed, verbal learning and visual learning. Our results
support that male schizophrenia patients had more cognitive impairment than females on reasoning and
problem solving, social cognition, processing speed, working memory, verbal learning and visual learning.
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Gender differences measured by 
the MATRICS consensus cognitive 
battery in chronic schizophrenia 
patients
Baohua Zhang1,2, Mei Han2, Shuping Tan1, Fu De Yang1, Yunlong Tan1, Shurong Jiang1, 
Xiangyang Zhang1,3 & Xu-Feng Huang  2
Using Repeatable Battery for the Assessment of Neuropsychological Status (RBANS), previous study 
showed significant gender differences for cognitive deficits in immediate and delayed memory in 
schizophrenia patients. However, RBANS does not include reasoning and problem solving, and social 
cognition. These cognitive functions can significantly affect the outcomes and daily life in patients. This 
study examined the gender differences of cognition using the measurement and treatment research to 
improve cognition in schizophrenia (MATRICS) consensus cognitive battery (MCCB), especially focusing 
on reasoning and problem solving, and social cognition in schizophrenia patients. The results showed 
that healthy controls exemplified better cognition than patients in both genders in all examined 
MCCB scores. Male healthy controls had better reasoning and problem solving and working memory 
than females, but these gender differences were not presented in schizophrenia patients. Also, male 
schizophrenia patients showed worse cognition than females on social cognition, processing speed, 
verbal learning and visual learning. Our results support that male schizophrenia patients had more 
cognitive impairment than females on reasoning and problem solving, social cognition, processing 
speed, working memory, verbal learning and visual learning.
Cognitive deficit is one of the core features of schizophrenia1. Cognitive deficit directly affect the quality of life 
and employment in schizophrenia patients2. Gender differences are recognized in brain neurotransmitter and 
receptors and function as well as their influence in behavior including in schizophrenia patients. Schizophrenia 
patients show gender differences in clinical symptoms, course and treatment outcome3. Several studies have 
reported gender differences in relation to cognitive deficits in schizophrenia4–6. An in-depth investigation of gen-
der difference of cognitive deficits could help us to guide preclinical and clinical research and possible new ideas 
for a better treatment for patients.
Although we and others have used the repeatable battery for the assessment of neuropsychological status 
(RBANS) to report that the immediate memory and delayed memory were poorer in male than female chronic 
schizophrenia patients7–9. RBANS was initially introduced to provide neuropsychological assessment in screen-
ing for dementia10. It has since been shown to be valid for other mental illnesses including schizophrenia11. The 
major weakness of RBANS is that its cognitive measurement does not include reasoning and problem solving, 
and social cognition. These cognitive domains can significantly affect quality of life and independent living skills 
in schizophrenia, including relapse, worsened symptoms, and resulting unemployment12–15. The gender differ-
ences of cognitive impairment on reasoning and problem solving, or social cognition have not been systemically 
investigated in schizophrenia patients. In addition, some studies failed to find any gender differences of cognitive 
deficits in schizophrenia patients, or found better cognition in male schizophrenia patients than females16,17. 
Therefore, the gender differences of cognitive function in schizophrenia patients remained controversial and 
deserve further investigation.
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Measurement and treatment research to improve cognition in schizophrenia (MATRICS) was originally 
developed by the US National Institute of Mental Health (NIMH). The primary goal of the NIMH-MATRICS was 
to encourage the development of pharmacological agents to improve cognition in schizophrenia18. The MATRICS 
consensus cognitive battery (MCCB) was widely developed to measure cognitive function in schizophrenia 
patients after the cognitive measure method has been evaluated based on its test-retest reliability, high utility as a 
repeated measure, relationship to functional outcome, practicality and tolerability, which was accepted by most 
medical researchers18. Importantly, the MCCB cognitive measure includes reasoning and problem solving and 
social cognition, which were important domains of cognitive deficits in schizophrenia. In recent years, MCCB for 
cognitive measurement has been translated into Chinese, and its clinical validity and test-retest reliability have 
been established between schizophrenia patients and health controls19. The MCCB has been applied in cognition 
studies for schizophrenia patients in Chinese population20,21.
To the best of our knowledge, no previous study has investigated the gender differences of cognitive deficits 
in schizophrenia patients in the Chinese Han population using MCCB. The purpose of this study was to verify: 
(1) whether or not schizophrenia patients had gender differences in cognitive deficits for reasoning and problem 
solving, and social cognition; (2) if the gender differences identified in our previous study9 using RBANS can be 
confirm using MCCB; and (3) whether the gender differences of cognitive deficits in schizophrenia were associ-
ated with specific clinical characteristics and symptoms.
Results
Demographic and clinical data in schizophrenia patients and healthy controls. Table 1 showed 
no significant difference between schizophrenia patients and healthy controls in age, gender and education. There 
were significant gender differences in the age at onset of illness and duration of illness (p < 0.001 or p < 0.05) 
in schizophrenia patients (Table 2). In addition, there were no significant differences between male and female 
schizophrenia patients in any of the PANSS scores, the ratio of typical to atypical antipsychotics, and the antipsy-
chotic dose (equivalent to chlorpromazine) (Table 2).
Cognitive performance in schizophrenia patients and healthy controls. After controlling for 
age and education, multivariate analysis of covariance revealed significant differences in all cognitive domains 
between schizophrenia patients and healthy controls (F1,191 = 28.6, p < 0.001). Furthermore, diagnosis (schiz-
ophrenia patients vs healthy subjects) was significantly different for the MCCB total and all subtest scores (all 
p < 0.001). Male schizophrenia patients had significantly lower cognitive MCCB total and subtest scores (all 
p < 0.001) than male healthy subjects, with effect sizes ranging from 0.79 to 2.09. Female patients also had sig-
nificantly lower cognitive MCCB total and subtest scores (all p < 0.001 or p < 0.01) than female healthy subjects, 
with effect sizes ranging from 0.42 to 1.35.
Multivariate analysis of covariance also revealed overall main effects for gender on symbol coding of process-
ing speed, reasoning and problem solving (both p < 0.001). Also, analysis showed significant gender x diagnosis 
interaction effects on working memory, verbal learning and visual learning (p < 0.01 or p < 0.05). To further 
analyze these two-way interactions, we compared cognitive function in schizophrenia patients or healthy controls 
separately by gender. Male schizophrenia patients performed poorer than females on symbol coding of processing 





(n = 160) F or χ2 P-value
Gender (male/female) 112/80 80/80 2.44 > 0.05
Age (years) 47.3 ± 7.9 44.7 ± 11.0 3.59 > 0.05
Education (years) 10.8 ± 2.1 10.0 ± 3.6 3.81 > 0.05
Table 1. Demographic characteristics in schizophrenia patients and healthy controls Mean ± SD (standard 
deviation).
Male Female F or χ2 p-value
Age (years) 47.6 ± 8.5 47.6 ± 7.1 0.48 0.49
Education (years) 10.6 ± 2.1 11.2 ± 2.1 3.73 0.06
Age at onset of illness 22.5 ± 5.4 25.7 ± 7.3 11.13 < 0.01
Duration of illness 24.9 ± 9.3 21.3 ± 10.2 5.75 < 0.05
Antipsychotic type (typicals/atypicals) 13/99 9/71 0.00 0.83
Antipsychotic dose (CPZ equivalents)(mg) 365.9 ± 312.8 392.1 ± 218.9 0.35 0.56
Score on positive symptom scale 12.0 ± 4.5 13.5 ± 5.7 3.66 0.06
Score on negative symptom scale 17.9 ± 5.2 17.8 ± 5.8 0.03 0.87
Score on general psychopathology scale 27.4 ± 5.4 28.1 ± 6.2 0.63 0.43
Total PANSS score 61.1 ± 11.2 63.0 ± 14.4 0.94 0.33
Table 2. Characteristics of patients with schizophrenia grouped by gender Note: Mean ± SD. 
CPZ = chlorpromazine; PANSS = the positive and negative syndrome scale.
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0.44 to 0.69 (Fig. 1). Furthermore, the gender differences assessment on symbol coding of processing speed and 
visual learning passed Bonferroni corrections (all p < 0.01) but verbal learning and social cognition did not pass 
Bonferroni corrections (all p > 0.05). Male healthy controls had better cognitive performance than females in 
working memory (including digital sequence and spatial span total), reasoning and problem solving (p < 0.01 
or p < 0.05), with effect sizes ranging from 0.39 to 0.42 (Fig. 1). Also, reasoning and problem solving and digital 
sequence of working memory passed Bonferroni corrections (all p < 0.05) but the spatial span total for working 
memory did not pass the Bonferroni corrections (p > 0.05) in healthy subjects.
Relationship between cognitive performance and clinical variables in schizophrenia 
patients. Multivariate regression analysis showed that MCCB total score was independently associated with 
PANSS negative symptom score (beta = −0.497, t = −4.016, p < 0.001) and gender (beta = 3.237, t = 2.325, 
p < 0.05). These factors together predicted 12% of the variance of the total MCCB score.
The symbol coding score of processing speed was independently associated with age (beta = −0.556, 
t = −6.044, p < 0.001), gender (beta = 6.088, t = 4.346, p < 0.001), education (beta = 1.029, t = 2.974, p < 0.01), 
and PANSS negative symptom score (beta = −0.323, t = −2.631, p < 0.01). These factors together predicted 37% 
of the variance of the symbol coding score.
Verbal learning was independently associated with age (beta = −0.556, t = −6.044, p < 0.001) and gender 
(beta = 6.088, t = 4.346, p < 0.001). These factors together predicted 18% of the variance in verbal learning.
Visual learning was independently associated with the following variables: duration of illness (beta = −0.294, 
t = −5.744, p < 0.001), gender (beta = 2.844, t = 2.757, p < 0.01), and PANSS negative symptom score 
(beta = −0.220, t = −2.420, p < 0.05). These factors together predicted 25% of the variance in visual learning.
Social cognition was independently associated with education (beta = 0.191, t = 3.325, p < 0.01), and PANSS 
negative symptom score (beta = −0.053, t = −2.396, p < 0.001). These factors together predicted 9% of the vari-
ance in social cognition.
Discussion
Compared to our previous study using RBANS cognitive measurement9, this study found more cognitive impair-
ments on reasoning and problem solving, social cognition, processing speed and working memory in male than 
female schizophrenia patients. This study also extended our previous study of cognitive deficits in both male 
and female schizophrenia patients. Moreover, we found that male schizophrenia patients showed more severe 
cognitive deficits than female patients in verbal learning and visual learning that was consistent with our previ-
ous using RBANS study9. Furthermore, schizophrenia patients showed greater cognitive deficits in all examined 
cognitive domains than healthy controls for both genders, which were also consistent with our previous study 
using RBANS9.
A direct comparison of reasoning and problem solving between male and female patients showed no dif-
ference, which differed from normal subjects that males perform better in reasoning and problem solving than 
females. Therefore, our study suggest that male schizophrenia patients may have more cognitive impairment than 
females on reasoning and problem solving, which is consistent with previous finding22. Male healthy controls 
exemplified better reasoning and problem solving than females, which is also consistent with previous studies that 
showed cognitive advantages in males than females on spatial reasoning tasks23.
Furthermore, our study suggested that social cognitive deficits were worse in male than female schizophrenia 
patients, which was similar to previous observations24. Our results were in a line with some previous rodent stud-
ies mimicking schizophrenia-like behavior. For example, a reduction in social interaction was observed in male, 
but not in female rats following neonatal treatment with domoic acid25. Folate-deficient mice showed reduced 
social interaction in males but not females26. However, the pathophysiological mechanisms underlying the gender 
differences in the social cognition for schizophrenia patients were not clear. Rodent study showed that serotonin 
Figure 1. The cognitive test scores by MCCB in schizophrenia patients and healthy controls. Subtest-1: Symbol 
coding of processing speed; Subtest-2: Digital sequence of working memory; Subtest-3: Spatial span total of 
working memory; Subtest-4: Verbal learning; Subtest-5: Visual learning; Subtest-6: Reasoning and problem 
solving; Subtest-7: Social cognition. ***p < 0.001, **p < 0.01 and *p < 0.05. SZ: Schizophrenia patients; 
HC: Healthy controls. MCCB: MATRICS (Measurement and Treatment Research to Improve Cognition in 
Schizophrenia) Cognitive Consensus Batterys.
www.nature.com/scientificreports/
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5-HT2A receptor expression was reduced in the prefrontal cortex, hypothalamus, and midbrain of social isolated 
male mice27. Human study showed that 5-HT2A receptor −1438 A/G polymorphism in the promoter region may 
influence social cognitive function in patients with schizophrenia28. These results suggested that 5-HT2A recep-
tor or their genetic variants may be contributed to the gender differences of social cognition in schizophrenia 
patients.
Processing speed is an important behavioural marker of the pathophysiology of schizophrenia29. This study 
found that male schizophrenia patients had worse symbol coding processing speed than females, which was 
consistent with previous studies30,31. Also, this study showed that gender was independently associated with the 
symbol coding processing speed in schizophrenia patients. In addition, the rat model also supported that males 
had worse processing speed that females32. These results suggested that gender difference exists in the processing 
speed in schizophrenia patients. The symbol coding processing speed in MCCB is similar with coding tasks of 
attention in RBANS (Table 3). However, our previous study did not find gender difference in attention for schiz-
ophrenia patients using RBANS9. The cognitive domains on attention did not distinguish subgroups (digit span 
and coding tasks) using our previous RBANS study, which may be the possible reason for the negative discovery 
of gender difference on attention9 (Table 3). Therefore, this distinction of subgroups using RBANS in cognitive 
analysis may be important in future studies.
A direct comparison of working memory between male and female patients showed no difference, which dif-
fered from normal subjects that that males perform better in working memory than females. Therefore, our study 
suggested that male schizophrenia patients may have more cognitive impairment than females, which is similar 
finding as previous report33. The rodent study also showed some less impairments in female than male in working 
memory34,35. The digital sequence of working memory in MCCB is equivalent to the digit span of attention in 
RBANS (Table 3). The spatial span total of working memory in MCCB has considerable overlap with the figure 
copy of visuospatial/constructional in RBANS (Table 3). Further, our previous study by Han et al. only addressed 
cognitive analysis by immediate memory, visuospatial/constructional, language and delayed memory and did 
not distinguish subgroups of these cognitive domains in RBANS9 (The details for subgroups of RBANS please see 
the Table 3). This could have led to some negative findings in gender differences of cognition on attention and 
visuospatial/constructional domains. In addition, other clinical study had opposite findings on gender difference 
in working memory impairment in schizophrenia patients which was that female schizophrenia patients had 
worse working memory than male patients36. Currently, we do not have a clearly explanation for the inconsistent 
findings. It could be due to inconsistent and complex factors tested that may result in heterogeneity in the schiz-
ophrenia diagnosis, the course of the disease, antipsychotic treatments, and ethnic background. Prefrontal cortex 
plays an important role in working memory37, which could warrant an imaging study to compare prefrontal 
cortical differences between male and female schizophrenia patients.
The impairments of verbal and visual learning were found in schizophrenia patients compared to healthy 
controls. Also, male schizophrenia patients had worse cognitive deficits than female patients on verbal and visual 
learning domains. Post-hoc comparisons of schizophrenia patients and healthy controls yield significant interac-
tions between gender and diagnosis (schizophrenia patients vs. healthy controls). Verbal and visual learning were 
independently associated with gender in schizophrenia patients. These results supported that male schizophrenia 
MCCB RBANS
Processing speed Immediate memory
Category fluency List learning d
Symbol coding a Story memory
Trail Making A Visuospatial/constructional
Attention/Vigilance Figure copy c
CPT-IP Line orientation
Working memory Language
Digital sequence b Picture naming
Spatial span total c Semantic fluency tasks
Verbal learning Attention
HVLT-R total d Digit span b
Visual learning Coding Tasks a
BVMT-R total e Delayed memory
Reasoning and problem 
solving List recall
Mazes (NAB) total List recognition
Social cognition Story recall
MSCEIT Figure recall e
Table 3. The lists of cognitive domains in MCCB and RBANS MCCB: Measurement and Treatment Research 
to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery; CPT-IP: Continuous 
Performance Test-Identical Pairs; HVLT: Hopkins Verbal Learning Test; BVMT: Brief Visuospatial Memory 
Test; NAB: Neuropsychological Assessment Battery; MSCEIT: Mayer-Salovey-Caruso Emotional Intelligence 
Test. RBANS: Repeatable Battery for the Assessment of Neuropsychological Status. a–eSymbols indicate the 
positive findings in MCCB, which they have the similar cognitive measure parameters with RBANS.
www.nature.com/scientificreports/
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patients had worse cognitive impairment than female patients on verbal and visual learning, which were consist-
ent with other studies36,38. Verbal learning is related to immediate memory in RBANS (Table 3). Visual learning 
is related to figure recall of delayed memory in RBANS (Table 3). Therefore, male schizophrenia patients had sig-
nificantly worse cognitive deficits than females on verbal and visual learning in the study, which were consistent 
with our previous RBANS results that male schizophrenia patients had worse immediate and delayed memory 
impairment than females9.
Compared to healthy controls, this study found significant cognitive deficits in all seven examined cognitive 
domains of MCCB in schizophrenia patients, which is consistent with ours and other previous studies9,39–41. 
Interestingly, our previous study observed a cognitive impairment trend in visuospatial/constructional domain 
in schizophrenia patients than healthy controls (p = 0.059)9. As described above, visuospatial/constructional 
domain mainly composed of figure copy and line orientation tasks in RBANS (Table 3). The figure copy of visu-
ospatial/constructional is mainly overlapping with spatial span total of working memory The line orientation task 
of visuospatial/constructional is also mainly overlapping with trail making A for speed of processing in MCCB. 
However, in this study, the trail making A for speed of processing and spatial span total of working memory 
were found to incur significant impairment in schizophrenia patients compared to healthy controls. These results 
prompted that it is important to analyse the visuospatial/constructional cognitive domain by subgroup (figure 
copy and line orientation tasks) in using RBANS.
The effect of worse cognition for male schizophrenia patients compared to females in several cognitive 
domains has been consistently identified by both our MCCB and RBANS studies. However, the pathophysi-
ological mechanism of gender difference of cognitive deficits in schizophrenia is not clear. Currently, neuro-
protective effects of sex hormones (especially estrogens) are among the most studied and accepted explanation 
for gender difference in cognition9,14,42,43. Moreover, gender differences in response to antipsychotics treatment 
could also contribute to the differential cognitive impairments in schizophrenia patients9,44–46, while some stud-
ies did not support such claim47–49. In addition, some studies suggested that an earlier onset of schizophrenia 
was associated with the seriousness of the disease, including cognitive deficits50. Therefore, it should be noted 
that male schizophrenia patients generally had an earlier age of onset for the illness and longer duration of 
illness than female patients in this study, which might be one of reason that male schizophrenia patients per-
formed worse cognitive deficits than females. However, other studies have failed to find differences in the cogni-
tive profiles of individuals with early or late-onset schizophrenia51,52. Also, the excitation/inhibition imbalance 
theory of biological psychiatry may explain the relative preferential effect of schizophrenic neuropathology on 
particular mental processes53. This theory supports that gender differences in different cognitive domain may 
have specific pathophysiology in schizophrenia patients. Also, a study suggested that gender specific differ-
ences in neurotransmitter levels in the medial prefrontal cortex and hippocampus may contribute to the gender 
differences of cognitive deficits in schizophrenia patients54. Nevertheless, the pathophysiological mechanism 
that resulted in better performance of cognition for females than males in schizophrenia patients still needs to 
further be investigated.
In addition, our regression analysis revealed significant correlation between the symbol coding of processing 
speed score and PANSS negative symptom score, visual learning and duration of illness. These results supported 
that cognitive deficits was significantly related to the severity of negative symptoms and duration of illness of 
schizophrenia.
This study has some limitations. Since this research is a phenomenological study, it does not explain the 
molecular mechanisms of the gender differences or the pathophysiology of cognition in schizophrenia. First, 
the schizophrenia patients in this study were of the chronic patients. Although there were no gender differences 
in antipsychotic dose (CPZ equivalents) and antipsychotic type (typical/atypical), the duration of illness in male 
patients were longer than female patients. We could not exclude that the gender effects of cognition in schizo-
phrenia patients might be caused by disease duration and chronic drug treatment. Second, the cross-sectional 
study provided a snapshot of the entire course of the disease. A future longitudinal study might help to reveal 
the effects of disease progression. Third, the patients were all inpatients and therefore these results might not be 
generalizable to all schizophrenia patients. Fourth, it should be mentioned that our results for spatial span of 
working memory, verbal learning and social cognition did not pass the Bonferroni corrections test. Therefore, 
these results should be carefully regarded. Furthermore, repeat analysis and larger sample size study might be 
conducted. Fifth, mental status, personal and family history of mental illness for healthy controls were assessed 
using unstructured interviews and were not assessed using structured interviews such as SCID. Therefore, 
we cannot completely exclude the healthy controls from the potential of being subject to weak psychiatric 
disorders.
In summary, compared to our previous using RBANS study, we have added new findings that male schiz-
ophrenia patients had worse cognitive impairment than females in symbol coding processing speed, working 
memory, reasoning and problem solving, and social cognition measured by MCCB. We also found significant 
gender differences in cognitive deficits in verbal and visual learning in schizophrenia patients, which were con-
sistent with our previous study measured by RBANS. MCCB covers an equivalent range of cognitive measure-
ments to RBANS and has additional advantaging in detecting deficits in reasoning, problem solving and social 
cognition in schizophrenia patients.
Materials and Methods
Ethics statement. A complete description of the study was given to all participants. All participants were 
provided with written informed consent. A psychiatrist evaluated all the participants to test whether they had 
the capacity to consent. The research procedure was explained during a detailed interview and the participants 
acknowledged they understood what they were required to do. Language appropriate to the participant’s level of 
comprehension and emotional readiness was used to maximise the understanding of the participants. If he/she 
www.nature.com/scientificreports/
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was willing to participate in the research but was unable to understand the complexity of the research processes, 
the research was simultaneously described to the parent or guardian and the patient. The parent or guardian then 
explained the research process to the participants using those methods that gauged the participant’s interest and 
maximised their understanding. In these situations, written consent was provided by the parent or guardian on 
behalf of the participant. If the participant did not agree to participate in the research study, they were not dis-
criminated against and were given the same treatment as the study participants.
Consent from study population. Informed consent has been obtained from the patients or their parents 
and guardians to use the results for analysis and use information for online open-access publication before sub-
jects were recruited. The study protocol was approved by the Institutional Review Board, Beijing HuiLongGuan 
Hospital, and all methods were performed in accordance with the relevant guidelines and regulations.
Participants. One hundred and ninety two schizophrenia patients (male/female = 112/80) were recruited 
using a cross-sectional naturalistic design at Beijing HuiLongGuan Hospital, a Beijing City owned psychiatric 
hospital. The diagnoses for each patient were made by two independent and experienced psychiatrists and con-
firmed by the Chinese version of Structured Clinical Interview for DSM-IV-TR Axis I Disorders. Research Version, 
Patient Edition (SCID-I/P)55. All patients were aged between 20 and 60 years, diagnosed with schizophrenia for 
at least 5 years, and were on stable doses of oral antipsychotic drugs for at least 12 months (ranging from 1 to 13 
years) prior to entry into the study. Antipsychotic drugs consisted of monotherapy with atypical antipsychotics 
including clozapine 50–600 mg/day (n = 86), risperidone 2–10 mg/day (n = 52), quetiapine 300–1000 mg/day 
(n = 13), olanzapine 5–20 mg/day (n = 5), aripiprazole 10 mg/day (n = 1), and typical antipsychotics including 
haloperidol 12–50 mg/day (n = 5), chlorpromazine 200 mg/day (n = 1), perphenazine 14–30 mg/day (n = 7), 
sulpiride 100–1000 mg/day (n = 6), and others (n = 16). The mean antipsychotic dose (as chlorpromazine equiva-
lents) was 379.2 ± 277.6 mg/day. Since admission, all patients received dietetically balanced hospital meals, which 
were occasionally supplemented by gifts (usually fruit), and patients had the opportunity to undertake about an 
hour of physical exercise every day.
Clinical assessment. We obtained a complete medical history and physical examination from all par-
ticipants, and participants with serious medical abnormalities were excluded. All schizophrenia patients were 
inpatients. All participants were Han Chinese recruited at the same period from the Beijing area. Both the schiz-
ophrenia patients and the healthy controls revealed a similar socioeconomic status and dietary patterns. Healthy 
controls (male/female = 80/80) were recruited from our local community. Current mental status and personal 
or family history of mental illness was assessed using unstructured interviews. None of the healthy controls pre-
sented a personal or family history of psychiatric disorders. Neither the patients with schizophrenia nor the 
healthy controls had a history of drug abuse or dependence.
Clinical assessments of patients were carried out by two psychiatrists who had more than five years of clinical 
practice experience and who were blind to the clinical status and treatment conditions assessed the participants’ 
psychopathology using the positive and negative syndrome scale (PANSS)56. To ensure consistent and reliable 
ratings, the two psychiatrists simultaneously attended a training session for standardizing their use of PANSS 
prior to the start of the study. Thereafter, they maintained an intra-class correlation coefficient of greater than 0.8 
on the PANSS at repeated assessments during the course of this study.
Cognitive assessment. All subjects were given cognitive function assessment using the MCCB18,57. A pre-
vious study by Zhou et al. at Beijing Huilong Guang Hospital showed that MCCB was valuable and reliable in 
assessing cognitive function in Chinese Han schizophrenia patients and health controls19. The MCCB is com-
prised of 10 standardized measures that are used to calculate cognitive functions in 7 domains and a global 
composite score. The MCCB battery consists of Trail Making Test Part A; Brief Assessment of Cognition in 
Schizophrenia: Symbol coding; Hopkins Verbal Learning Test (HVLT); Wechsler Memory Scale Spatial span; 
Digital Sequence Test; Neuropsychological Assessment Battery (NAB): Mazes; Brief Visuospatial Memory Test 
(BVMT); Category Fluency; Mayer-Salovey-Caruso Emotional Intelligence Test (MSCEIT): Managing Emotions; 
and the Continuous Performance Test: Identical Pairs. The seven MCCB domains were: processing speed, atten-
tion/vigilance, working memory, verbal learning, visual learning, reasoning and problem solving and social 
cognition58.
Statistical Analysis. Group comparisons on the demographic and clinical variables used Chi squared or 
Fisher exact tests for the categorical variables and Student t-tests or analysis of variance (ANOVA) for the con-
tinuous variables. For the MCCB comparisons, we included age and education as covariates in the multivariate 
analyses of covariance (MANCOVA). We tested the main effect of diagnose (schizophrenia patients vs healthy 
controls), gender (male vs female) and diagnosis x gender. Effect sizes were also calculated for the two-way 
comparisons and represented the mean difference, in standard deviation units, between the groups of interest. 
MANCOVA was used to further analyse these differences in cognitive functions. Bonferroni corrections were 
applied to each test to adjust for multiple testing. To analysis the amount of variance in cognitive functioning 
explained by the psychopathological variables, first-order multiple linear models were estimated by using the 
least-squares estimator, while controlling for several potential confounders including age, gender, education, 
duration of illness and PANSS (positive, negative, general pathological symptoms and the total score). To select a 
subset of variables which were associated with the response, stepwise selection was used, where inclusion factors 
for variable selection were set at a p-value < 0.05.
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7Scientific RepoRts | 7: 11821  | DOI:10.1038/s41598-017-12027-w
References
 1. Elvevag, B. & Goldberg, T. E. Cognitive impairment in schizophrenia is the core of the disorder. Crit Rev Neurobiol 14, 1–21 (2000).
 2. Tomida, K. et al. Relationship of psychopathological symptoms and cognitive function to subjective quality of life in patients with 
chronic schizophrenia. Psychiatry Clin Neurosci 64, 62–9 (2010).
 3. Ran, M. S., Mao, W. J., Chan, C. L., Chen, E. Y. & Conwell, Y. Gender differences in outcomes in people with schizophrenia in rural 
China: 14-year follow-up study. Br J Psychiatry 206, 283–8 (2015).
 4. Zhang, X. Y. et al. Gender differences in never-medicated first-episode schizophrenia and medicated chronic schizophrenia patients. 
J Clin Psychiatry 73, 1025–33 (2012).
 5. Wisner, K. M., Elvevag, B., Gold, J. M., Weinberger, D. R. & Dickinson, D. A closer look at siblings of patients with schizophrenia: 
the association of depression history and sex with cognitive phenotypes. Schizophr Res 126, 164–73 (2011).
 6. Halari, R., Mehrotra, R., Sharma, T., Ng, V. & Kumari, V. Cognitive impairment but preservation of sexual dimorphism in cognitive 
abilities in chronic schizophrenia. Psychiatry Res 141, 129–39 (2006).
 7. Fiszdon, J. M., Silverstein, S. M., Buchwald, J., Hull, J. W. & Smith, T. E. Verbal memory in schizophrenia: sex differences over 
repeated assessments. Schizophr Res 61, 235–43 (2003).
 8. Goldstein, J. M. et al. Are there sex differences in neuropsychological functions among patients with schizophrenia? American 
Journal of Psychiatry 155, 1358–64 (1998).
 9. Han, M. et al. Gender differences in cognitive function of patients with chronic schizophrenia. Prog Neuropsychopharmacol Biol 
Psychiatry 39, 358–63 (2012).
 10. Randolph, C., Tierney, M. C., Mohr, E. & Chase, T. N. The Repeatable Battery for the Assessment of Neuropsychological Status 
(RBANS): preliminary clinical validity. J Clin Exp Neuropsychol 20, 310–9 (1998).
 11. Gold, J. M., Queern, C., Iannone, V. N. & Buchanan, R. W. Repeatable battery for the assessment of neuropsychological status as a 
screening test in schizophrenia I: sensitivity, reliability, and validity. American Journal of Psychiatry 156, 1944–50 (1999).
 12. Mohamed, S. et al. Relationship of cognition and psychopathology to functional impairment in schizophrenia. Am J Psychiatry 165, 
978–87 (2008).
 13. Twamley, E. W. et al. Generalized cognitive impairments, ability to perform everyday tasks, and level of independence in community 
living situations of older patients with psychosis. Am J Psychiatry 159, 2013–20 (2002).
 14. Green, M. F., Kern, R. S., Braff, D. L. & Mintz, J. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring 
the “right stuff ”? Schizophr Bull 26, 119–36 (2000).
 15. Pinkham, A. E. Social cognition in schizophrenia. Journal of Clinical Psychiatry 75(Suppl 2), 14–9 (2014).
 16. Ochoa, S., Usall, J., Cobo, J., Labad, X. & Kulkarni, J. Gender differences in schizophrenia and first-episode psychosis: a 
comprehensive literature review. Schizophr Res Treatment 2012, 916198 (2012).
 17. Brebion, G. et al. Cognitive correlates of verbal memory and verbal fluency in schizophrenia, and differential effects of various 
clinical symptoms between male and female patients. Schizophrenia Research 147, 81–5 (2013).
 18. Green, M. F. et al. Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference 
to select cognitive domains and test criteria. Biol Psychiatry 56, 301–7 (2004).
 19. Zou, Y. Z. et al. Clinical reliability and validity of the Chinese version of Measurement and Treatment Research to Improve 
Cognition in Schizophrenia Consensus Cognitive Battery. Chin J Psychiatry 42(1), 29–33 (2009).
 20. Shi, C., He, Y., Cheung, E. F., Yu, X. & Chan, R. C. An ecologically valid performance-based social functioning assessment battery 
for schizophrenia. Psychiatry Research 210, 787–93 (2013).
 21. Tan, S. P. et al. Smoking, MATRICS consensus cognitive battery and P50 sensory gating in a Han Chinese population. Drug & 
Alcohol Dependence 143, 51–7 (2014).
 22. Nuechterlein, K. H. et al. Identification of separable cognitive factors in schizophrenia. Schizophr Res 72, 29–39 (2004).
 23. Geary, D. C., Saults, S. J., Liu, F. & Hoard, M. K. Sex differences in spatial cognition, computational fluency, and arithmetical 
reasoning. J Exp Child Psychol 77, 337–53 (2000).
 24. Vaskinn, A. et al. Sex differences in neuropsychological performance and social functioning in schizophrenia and bipolar disorder. 
Neuropsychology 25, 499–510 (2011).
 25. Ryan, C. L. et al. Altered social interaction in adult rats following neonatal treatment with domoic acid. Physiology & Behavior 102, 
291–5 (2011).
 26. Schaevitz, L. R. et al. Glutamate carboxypeptidase II and folate deficiencies result in reciprocal protection against cognitive and 
social deficits in mice: implications for neurodevelopmental disorders. Developmental Neurobiology 72, 891–905 (2012).
 27. Bibancos, T., Jardim, D. L., Aneas, I. & Chiavegatto, S. Social isolation and expression of serotonergic neurotransmission-related 
genes in several brain areas of male mice. Genes Brain Behav 6, 529–39 (2007).
 28. Lo, C. H. et al. Emotional management and 5-HT2A receptor gene variance in patients with schizophrenia. Biol Psychol 83, 79–83 
(2010).
 29. Bachman, P. et al. Deconstructing processing speed deficits in schizophrenia: application of a parametric digit symbol coding test. 
Schizophr Res 118, 6–11 (2010).
 30. Longenecker, J., Dickinson, D., Weinberger, D. R. & Elvevag, B. Cognitive differences between men and women: a comparison of 
patients with schizophrenia and healthy volunteers. Schizophrenia Research 120, 234–5 (2010).
 31. Tsai, P. C., McDowd, J., Tang, T. C. & Su, C. Y. Processing speed mediates gender differences in memory in schizophrenia. Clinical 
Neuropsychologist 26, 626–40 (2012).
 32. Thomson, D. M., McVie, A., Morris, B. J. & Pratt, J. A. Dissociation of acute and chronic intermittent phencyclidine-induced 
performance deficits in the 5-choice serial reaction time task: influence of clozapine. Psychopharmacology 213, 681–95 (2011).
 33. Malaspina, D. et al. Olfaction and cognition in schizophrenia: sex matters. Journal of Neuropsychiatry & Clinical Neurosciences 24, 
165–75 (2012).
 34. Babovic, D. et al. Phenotypic characterization of cognition and social behavior in mice with heterozygous versus homozygous 
deletion of catechol-O-methyltransferase. Neuroscience 155, 1021–9 (2008).
 35. Hill, R. A. et al. Sex-specific disruptions in spatial memory and anhedonia in a “two hit” rat model correspond with alterations in 
hippocampal brain-derived neurotrophic factor expression and signaling. Hippocampus 24, 1197–211 (2014).
 36. Lecardeur, L., Mendrek, A. & Stip, E. Sexual dimorphism of spatial working memory profiles in schizophrenia. Cognitive 
Neuropsychiatry 15, 397–405 (2010).
 37. Tan, H. Y., Callicott, J. H. & Weinberger, D. R. Prefrontal cognitive systems in schizophrenia: towards human genetic brain 
mechanisms. Cogn Neuropsychiatry 14, 277–98 (2009).
 38. Markham, J. A., Taylor, A. R., Taylor, S. B., Bell, D. B. & Koenig, J. I. Characterization of the cognitive impairments induced by 
prenatal exposure to stress in the rat. Front Behav Neurosci 4, 173 (2010).
 39. Han, M. et al. Cognitive differences in schizophrenia on long-term treatments with clozapine, risperidone and typical antipsychotics. 
Int Clin Psychopharmacol 30, 89–95 (2015).
 40. Keefe, R. S. Cognitive deficits in patients with schizophrenia: effects and treatment. J Clin Psychiatry 68(Suppl 14), 8–13 (2007).
 41. Kern, R. S. et al. The MCCB impairment profile for schizophrenia outpatients: results from the MATRICS psychometric and 
standardization study. Schizophr Res 126, 124–31 (2011).
 42. Culmsee, C. et al. Neuroprotection by estrogens in a mouse model of focal cerebral ischemia and in cultured neurons: evidence for 
a receptor-independent antioxidative mechanism. J Cereb Blood Flow Metab 19, 1263–9 (1999).
www.nature.com/scientificreports/
8Scientific RepoRts | 7: 11821  | DOI:10.1038/s41598-017-12027-w
 43. McEwen, B. S., Akama, K. T., Spencer-Segal, J. L., Milner, T. A. & Waters, E. M. Estrogen effects on the brain: actions beyond the 
hypothalamus via novel mechanisms. Behav Neurosci 126, 4–16 (2012).
 44. Rubin, L. H., Haas, G. L., Keshavan, M. S., Sweeney, J. A. & Maki, P. M. Sex difference in cognitive response to antipsychotic 
treatment in first episode schizophrenia. Neuropsychopharmacology 33, 290–7 (2008).
 45. Koolschijn, P. C. & Crone, E. A. Sex differences and structural brain maturation from childhood to early adulthood. Dev Cogn 
Neurosci 5, 106–18 (2013).
 46. Neufang, S. et al. Sex differences and the impact of steroid hormones on the developing human brain. Cereb Cortex 19, 464–73 
(2009).
 47. Shumaker, S. A. et al. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in 
postmenopausal women: Women’s Health Initiative Memory Study. JAMA 291, 2947–58 (2004).
 48. Espeland, M. A. et al. Conjugated equine estrogens and global cognitive function in postmenopausal women: Women’s Health 
Initiative Memory Study. JAMA 291, 2959–68 (2004).
 49. Daban, C. et al. Cognitive dysfunctions in medicated and unmedicated patients with recent-onset schizophrenia. Journal of 
Psychiatric Research 39, 391–8 (2005).
 50. Goldberg, X. et al. Neurodevelopmental liability to schizophrenia: the complex mediating role of age at onset and premorbid 
adjustment. Schizophr Res 133, 143–9 (2011).
 51. Jeste, D. V. et al. Clinical and neuropsychological characteristics of patients with late-onset schizophrenia. Am J Psychiatry 152, 
722–30 (1995).
 52. Sachdev, P., Brodaty, H., Rose, N. & Cathcart, S. Schizophrenia with onset after age 50 years. 2: Neurological, neuropsychological and 
MRI investigation. Br J Psychiatry 175, 416–21 (1999).
 53. Anticevic, A. & Lisman, J. How Can Global Alteration of Excitation/Inhibition Balance Lead to the Local Dysfunctions That 
Underlie Schizophrenia? Biol Psychiatry 81, 818–820 (2017).
 54. Bitanihirwe, B. K., Weber, L., Feldon, J. & Meyer, U. Cognitive impairment following prenatal immune challenge in mice correlates 
with prefrontal cortical AKT1 deficiency. Int J Neuropsychopharmacol 13, 981–96 (2010).
 55. Phillips, M. & Liu, X. Adapted Chinese version of Structured Clinical Interview for DSM-IV-TR Axis I Disorders. Research Version, 
Patient Edition(SCI-I/P) by Michael B. First, Robert L. Spitzer, Miriam Gibbon, and Janet B. W. Williams. Shang: Suicide Reseach 
and Prevention Center, Shanghai Mental Health Center. (2011).
 56. Kay, S. R., Fiszbein, A. & Opler, L. A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13, 
261–76 (1987).
 57. Nuechterlein, K.H. & Green, M.F. MATRICS Consensus Cognitive Battery. Los Angeles: MATRICS Assessmentt, Inc. (2006).
 58. Barch, D. M. et al. Selecting paradigms from cognitive neuroscience for translation into use in clinical trials: proceedings of the third 
CNTRICS meeting. Schizophr Bull 35, 109–14 (2009).
Acknowledgements
This study was funded by grants from the Capital Clinical Characteristic Research and Translation Foundation 
(Z171100001017022), China, the National Health and Medical Research Council of Australia (MH635245) and 
the Stanley Medical Institute (03T-459 and 05T-726). We thank the patients and families for their support and 
participation. We also thank Beijing Huilongguan Hospital, China, for a clinical interview with subjects and 
collection of blood samples.
Author Contributions
X.Y.Z. and X.-F.H. were responsible for the study design. B.H.Z., S.R.J. and S.P.T. were responsible for recruiting 
the patients, performing the clinical ratings and collecting the samples. B.H.Z., M.H., S.P.T. and X.-F.H. were 
involved in developing the ideas and editing the manuscript. B.H.Z. and M.H. were involved in writing the 
protocol. B.H.Z., M.H. and S.P.T. contributed equally to this work. F.D.Y. and Y.L.T. helped the data analysed and 
revised the manuscript. All of the authors have contributed to and approved the final manuscript.
Additional Information
Competing Interests: The authors declare that they have no competing interests.
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2017
